Total eyes | 126 |
Patients, n (%) | 126 |
Female | 97 (77) |
Male | 29 (33) |
Age, mean±SD (years) | 79.5 (8.9) |
Mean BCVA, mean±SD (ETDRS letters) | 63.7 (14.8) |
Follow-up time, mean±SD (months) | 22.9 (13.5) |
Previous anti-VEGF treatment, mean±SD, n | 10.4 (6.5) |
IVI interval, mean±SD (months) | 2.35 (1.42) |
CNV classification, n (%) | |
Type 1 | 107 (85) |
Type 2 | 21 (15) |
BCVA, Best Corrected Visual Acuity; CNV, choroidal neovascularisation; IVI, intravitreal injection; VEGF, vascular endothelial growth factor.